Cut off the emergency programme cancer cells use to survive treatment
When attacked, cells switch on a survival programme that buys them time to adapt. Blocking that programme could turn a partial response into a complete one.
The integrated stress response, heat shock factor 1 activity and autophagy are rapidly induced after targeted therapy and support survival during the adaptation window. Inhibitors of eIF2B-mediated stress signalling, HSF1 and autophagy exist at various stages of development. The proposal is combination timed to the adaptation window (the first days after therapy initiation) rather than continuous co-dosing.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
Pages like this
not linked directly; found by shared links- IdeaKill the sleeping survivor cells with iron-dependent cell death
Shares Drug resistance (primary and acquired), Minimal / molecular residual disease (MRD), Acquired resistance to every therapy.
- IdeaStarve the survivors: target the energy pathway drug-tolerant cells switch to
Shares Drug resistance (primary and acquired), Minimal / molecular residual disease (MRD), Acquired resistance to every therapy.
- IdeaBlock the chemical switch that lets cells hide from treatment
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaTurn off the error-prone repair that manufactures resistance mutations
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaMake post-progression sampling a condition of accelerated approval
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaEvery resistance mechanism found in a patient must be rebuilt in the laboratory
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaSMART designs to test treatment strategies, not just single drugs
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaFund a biopsy at progression, every time, as standard care
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.